Recommendations for Using Pneumococcal Vaccines among Adults
|
|
- Erica Bryant
- 5 years ago
- Views:
Transcription
1 Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar February 2016 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases Division of Bacterial Diseases
2 ACIP Recommendations through 2012: Pneumococcal Polysaccharide Vaccine (PPSV23) All adults 65 yrs and older Adults years old with the following conditions Advisory Committee on Immunization Practices, MMWR
3 Age-specific incidence of invasive pneumococcal disease, U.S., 1998 Incidence (cases per 100,000) < Age (years) 3
4 Conjugate Vaccines Benefit the Unvaccinated: Rates of IPD Caused by PCV7 Serotypes, A d u lts 1 8y e a rso ld PCV7 introduction 2009 vs. baseline 65+: -97%(-96,-98) 50-64: -92% (-89,-94) 18-49: -96 (-94,-97) Moore, IDSA, 2009
5 Burden of pneumococcal disease among adults 65 years of age Adults 65 years at increased risk for pneumococcal disease and serious illness from the major clinical syndromes associated with it Case-fatality rate for pneumococcal bacteremia is ~15% overall, but as high as 60% among adults 65 years ~18,000 fatal cases of pneumococcal disease am ong adults 65 years each year in the U nited St at es 6
6 13-valent Pneumococcal Conjugate Vaccine (PCV13) for Adults Licensed for use among adults >50 years old on 12/30/11 FDA approved under the Accelerated Approval Pathway Based on non-inferior immunogenicity compared to PPSV23 Indications Prevention of pneumococcal disease (including pneumonia and invasive disease) in adults 50 years of age and older Prevention of disease caused by Streptococcus pneumoniaeserotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F Post-approval condition of licensure: Randomized controlled trial of PCV13 against pneumococcal pneumonia among adults >65 years old in the Netherlands (CAPiTA) 8
7 ACIP Recommendations in 2012 Deferred recommendation for adults >65 years old until more data available Efficacy against pneumonia (CAPiTA) Indirect (herd) effects of PCV13 use in children Recommended a dose of PCV13 in sequence with PPSV23 for adults with immunocompromising conditions, functional or anatomic asplenia, CSF leaks or cochlear implants 9
8 Why did ACIP recommend PCV13 for immunocompromised adults?
9 Incidence of IPD in adults aged years with selected underlying conditions, United States, fold increased risk Cases per 100,000 persons fold increased risk HEALTHY CVD DIABETES PULMONARY KIDNEY LIVER ALCOHOL HIV/AIDS HEMATOLGICAL CANCER Kyaw, JID 2005;192:377-86
10 Trends in IPD rates among adults yrs old with & without HIV-infection, before and after PCV7 introduction, Adults with HIV infection Adults without HIV infection 6-8/ 100K 64 / 100K Cohen, AIDS 2010;24(14):
11 PCV efficacy against Invasive Pneumococcal Disease (IPD) Double-blind, randomized, placebo-controlled Efficacy trial among HIV-Infected Adults in Malawi (N=496) 2 doses of PCV7 given 4 weeks apart Endpoint Vaccine Efficacy (95% CI) PCV7-serotype IPD 74% (30%, 90%) French N, et.al. N Engl J Med 2010;362:
12 Immunogenicity of PCVs in immunocompromised adults PCV does elicit an immune response in HIV+ and cancer patients 1,2,3,4,5,6 Response following a single dose of PCV is as good or better than PPV23 (both in vaccine naive or previously vaccinated) 1,2,3 Studies with sequential vaccination show similar or improved immune response if PCV given first 1,2,3 Revaccination with PCV show similar immunogenicity compared to the first dose 4 1. Feikin Diag Lab Immunology 2004, 2. Lesprit AIDS 2007, 3. Penaranda AIDS Miro JID, Chan JID, Crum JID, 2010
13 In adults with immunocompromising conditions, should we use PCV13, PPSV23 or Both? Proportion of IPD by vaccine serotype, 2010 Immunocompromised 29% 50% 21% 21% of disease due to serotypes in PPSV23 not covered by PCV13 Opportunity for broader serotype protection through use of BOTH vaccines PCV13 PPV23/NonPCV13 Other CDC, ABCs, unpublished, 2011
14 Conclusions for high-risk adults Extremely high burden of disease among immunocompromised adults Indirect effects of PCV13 use in children unlikely to eliminate PCV13 serotypes from immunocompromised adults Benefits of PCV13 use in this group outweigh the harms PCV13 alone may not provide adequate coverage of serotypes causing disease Combined regimen of PCV13 and PPSV23 likely better than either vaccine alone ACIP Decision: Benefits likely outweigh harms and both PCV13 and PPSV23 should be recommended for adults with immunocomromising conditions
15 Vaccination Sequence Dat a for PCV followed by PPSV 3 studies in HIV+ show that antibodies non-inferior or superior when PCV given prior to PPSV Phase III studies in immunocompetent show that PCV13 + PPSV23 > PPSV23 + PCV for 11/12 serotypes Dat a for PPSV followed by PCV In 1 study in HIV+ in Uganda, PPSV 5 yrs prior did not affect response to PCV In 1 study in HIV+ in US, there was no difference in immunogenicity between PCV and PPSV given 3-8 years after PPSV Data support use of PCV13 followed by PPSV23
16 Interval between vaccines What is the optimal interval between PCV and PPSV? No studies have been designed to test the optimal interval & 2 month intervals immunocompetent older 12 month intervals All intervals showed significant increases in antibody as well as non-inferior or superior response compared to PPSV alone What is the optimal interval between PPSV and PCV? No studies have been designed to test the optimal interval Studies in immunocompetent suggest blunting of immune response <5 years after PPSV No evidence of reduced immunogenicity in HIV+ with PCV 5 years after PPSV
17 Recommendation for PCV13 and PPSV23 for high risk adults Vaccine naïve adults: PCV13 dose is recommended to be given before PPSV23, whenever possible PPSV23 should be given at least 8 weeks after a dose of PCV13 Recommendations for 2 nd dose of PPSV and a dose at age 65 years or older remain unchanged PPSV23-immunized adults A dose of PCV13 is recommended to be given to adults with immunocompromising conditions who received 1 or more doses of PPSV23 1 or more years after the last PPSV23 dose Tot al number and interval between PPSV23 doses unchanged from current recommendations 17
18 Prevention of pneumococcal disease am ong adults 19 years w ith high risk conditions Current guidelines Use of PCV13 and PPSV23 for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) remain unchanged ml/mm6140a4.htm 20
19 Prevention of pneumococcal disease among adults 19 years w ith functional or anatomic asplenia or immunocompromising conditions PCV13 + PPSV23 + PPSV23 (@< 65 years) (@< 65 years) (@<65 years) * 8 weeks 5 years + PPSV23 (@ 65 years) 21
20 Prevention of pneumococcal disease among adults 19 years w ith cochlear implants or CSF leaks PCV13 + PPSV23 + (@< 65 years) (@< 65 years) PPSV23 (@ 65 years) 8 weeks 5 years 22
21 Why did ACIP recommend PCV13 for adults >=65 years old?
22 New Evidence Supporting PCV13 use among adults, CAPiTA results Study/population CAPITA ~85,000 Adults 65+ Netherlands Endpoint Vaccine Efficacy (95% CI) PCV13-serotype IPD 75% (41%, 91%) PCV13-serotype non-bacteremic pneumonia 45% (14%, 65%) CAPITA, ACIP June
23 Summary of evidence supporting PCV13 use among adults >65 years of age Prevents IPD and non-bacteremic pneumonia 1 75% reduction in vaccine type IPD 45% reduction in vaccine type non-bacteremic pneumonia Immune response non-inferior or improved (for some serotypes) for PCV13 (or PCV7) vs. PPSV23 2,3 Safety demonstrated in clinical trials 1 CAPITA, June 2014 ACIP 2 Phase III trials, Pfizer, ACIP 2011, DeRoux et al. CID 2008, Goldblatt et al
24 Summary of evidence supporting PCV13 use among adults >65 years of age Vaccine preventable disease burden remaining among adults >65 years Estimated 2,600 PCV13 type IPD cases in Over 50,000 PCV13-type inpatient CAP 2 In the short-term, PCV13 likely provides adequate coverage of disease causing serot ypes 20-25% IPD due to PCV13 types 1 ~10% of all CAP due to PCV13 types 2 1 Active Bacterial Core Surveillance, Estimat e based on studies using serotype-specific urine antigen test, Pfizer 12
25 PCV13 now recommended in series w ith P P S V 2 3 fo r a ll a d u lts 6 5 y e a rs 13
26 A d u lts 65 years of age with no previous pneumococcal vaccine (PCV13 or PPSV23) or unknown vaccination history Recommendation Administer a dose of PCV13 first, followed by a dose of PPSV23 Guidance on intervals for sequential use A dose of PPSV23 should be given at least 1year* following a dose of PCV13. The two vaccines should not be co-administered. If a dose of PPSV23 was inadvertently given earlier than the recommended interval, the dose need not be repeated. *June 2015 ACIP vote 14
27 PCV13-naïve adults 65 years of age previously vaccinated with PPSV23 Recommendation Administer a dose of PCV13 Guidance on intervals for sequential use Administer PCV13 at least 1 year after the receipt of the most recent PPSV23 dose For those for whom an additional dose of PPSV23 is indicated, administer it at least 1 year* after PCV13 and at least 5 years after the most recent dose of PPSV23 *June 2015 ACIP vote 17
28 PCV13-naïve adults 65 years of age previously vaccinated with PPSV23 PPSV23 + PCV13 (@ 65 years) >1 year >5 years PPSV23 + PCV13 + PPSV23 (@< 65 years) (@ 65 years) (@ 65 years) * 1 year >1 year 18
29 September 19, 2014 / 63(37); ; October 12, 2012, Vol 61, #40; June 28, 2013 / 62(25); ; December 10, 2010 / 59(RR11);1-18 June 28, 2013 / 62(25); Intervals Between the Two Pneumococcal Vaccines Incorporating June 2015 Changes Age groups 19 years Underlying conditions PCV13 PPSV23 PPSV23 PCV13 High-risk immunocompetent (CSF leak, cochlear implants) Functional or anatomic asplenia Immunocompromised 8 weeks 1 year 65 years NA 1 year 1 year
30 Indications for PCV13 and PPSV23 Advisory Committee on Immunization Practices, MMWR 2012
31 Prevention of pneumococcal disease among adults 19 years w ith chronic medical conditions PPSV23 + (@< 65 years) PCV13 (@ 65 years) PPSV23 (@ 65 years) >1 year 5 years 23
32 PATIENT SCENARIOS 24
33 A 65 year old female patient with no underlying medical conditions and no previous pneumococcal vaccinations Administer vaccines as follows: 1 dose of PCV13 now 1 dose of PPSV23 1 year after administering PCV13 Rationale: Patient scenario #1 She is 65 years old and has no history of pneumococcal vaccination, so she is recommended both pneumococcal vaccines 33
34 A 67 year old male patient with no underlying medical conditions who received a dose of PPSV23 at age 65 years Administer vaccines as follows: 1 dose of PCV13 now Rationale: He is 65 years old Patient scenario #2 It has been 1 year since PPSV23 Only 1 dose of PPSV23 is recommended for adults 65 years 34
35 A 66 year old male patient with cochlear implants who received a dose of PPSV23 at age 55 years Administer vaccines as follows: 1 dose of PCV13 now 1 dose of PPSV23 1 year after administering PCV13 Rationale: He is 65 years old Patient scenario #3 At least 1 year has passed since he received PPSV23 It s been 5 years since his previous PPSV23 dose 35
36 A 66 year old female patient infection with HIV who received a dose of PPSV23 at ages 52, 57, and 65 years and a dose of PCV13 at 64 years Do not administer any vaccines Rationale: Patient scenario #4 Only 1 dose of PCV13 is recommended in an adult s lifetime Only 1 dose of PPSV23 is recommended for adults 65 years 36
37 Standards for Adult Immunization Practices Assess the immunization status of all your patients Strongly recommend vaccines that patients need Administer needed vaccines or refer patients to a vaccinating provider Document vaccines received by your patients 37
38 CDC Resources Clinician: Adult immunization information/schedule Patient: Education materials on adult immunization Implementation of Standards Pneumococcal disease and vaccine resources The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. National Center for Immunization & Respiratory Diseases Division of Bacterial Diseases
Recommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar July 2017 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationUse of 13-valent Pneumococcal Conjugate Vaccine and 23-valent Polysaccharide Vaccine in Adults with Immunocompromising Conditions
Use of 13-valent Pneumococcal Conjugate Vaccine and 23-valent Polysaccharide Vaccine in Adults with Immunocompromising Conditions Tamara Pilishvili, MPH Respiratory Diseases Branch National Center for
More information9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Pneumococcal Disease and Pneumococcal Vaccines Adult Track Chapter 17 Photographs and images included
More informationStreptococcus pneumoniae CDC
Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationPneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
More informationMeasure #111 (NQF 0043): Pneumococcal Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health
Measure #111 (NQF 0043): Pneumococcal Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health 2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process
More informationTo view past issues, go to: The New 13-Valent Pneumococcal Conjugate Vaccine (PCV13)
From the Texas Department of State Health Services Immunization Branch The goal of the Vaccine Advisory is to disseminate, in a timely manner, practical information related to vaccines, vaccine-preventable
More informationCall-to-Action: Recognizing the Burden of Vaccine- Preventable Diseases
Call-to-Action: Recognizing the Burden of Vaccine- Preventable Diseases Burden of Vaccine-Preventable Diseases Each Year 200,000 hospitalizations due to influenza As many as 36,000 deaths 29,100 cases
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More informationGetting national guidelines into practice: It takes more than education
Getting national guidelines into practice: It takes more than education AI Collaborative Group 2 September 12, 2017 Lynette M. Wachholz, MN, ARNP, CPHQ Email: lwachholz@everettclinic.com The Everett Clinic
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH* California Immunization Coalition Summit Riverside, California April 26, 2015 *Representing the Immunization Action Coalition, Saint Paul, MN Advisory
More informationACTIVITY DESCRIPTION Target Audience Learning Objectives
ACTIVITY DESCRIPTION Target Audience This activity is designed as a comprehensive approach to address the practice needs of primary care providers, including primary care physicians, doctors of osteopathy,
More informationACTIVITY DESCRIPTION Target Audience Learning Objectives
ACTIVITY DESCRIPTION Target Audience This activity is designed as a comprehensive approach to address the practice needs of primary care providers, including primary care physicians, doctors of osteopathy,
More informationPneumococcal vaccines
Pneumococcal vaccines Marco Aurélio Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Challenges in establishing the baseline burden of disease, before implementing a vaccination program S. pneumoniae disease
More informationVaccines for Primary Care Pneumococcal, Shingles, Pertussis
Vaccines for Primary Care Pneumococcal, Shingles, Pertussis Devang Patel, M.D. Assistant Professor Chief of Service, MICU ID Service University of Maryland School of Medicine Pneumococcal Vaccine Pneumococcal
More informationPNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID
PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID Objectives of Lecture Know the quality of current evidence based guidelines on immunization Appreciate the performance of pneumonia vaccines in terns
More informationMeasure #111 (NQF 0043): Pneumonia Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health
Measure #111 (NQF 0043): Pneumonia Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:
More informationthe benefits and potential side effects of pneumococcal immunization; and
F883 483.80(d) Influenza and pneumococcal immunizations 483.80(d)(1) Influenza. The facility must develop policies and procedures to ensure that- (i) Before offering the influenza immunization, each resident
More informationPneumoccocal vaccines in the elderly (conjugated vs polysaccharides)
Aging and Immunity II Campus Novartis, Siena April 24, 2012 Pneumoccocal vaccines in the elderly (conjugated vs polysaccharides) Paolo Bonanni Department of Public Health University of Florence, Italy
More informationVaccines in Immunocompromised hosts
Vaccines in Immunocompromised hosts Carlos del Rio, MD Emory Center for AIDS Research October 2013 Immunocompromised hosts Number has increased rapidly in the past decades Broad term that encompasses different
More informationPneumococcal Vaccine Effectiveness. Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA
Pneumococcal Vaccine Effectiveness Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA Overview Possible effectiveness outcomes for pneumococcal vaccines Pre-licensure
More informationIncidence per 100,000
Streptococcus pneumoniae Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: March 2007 Background
More informationACTIVITY DESCRIPTION. Reminder
1 ACTIVITY DESCRIPTION Target Audience This activity is designed as a comprehensive approach to address the practice needs of primary care providers, including primary care physicians, doctors of osteopathy,
More informationUpdate on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017
Centers for for Disease Disease Control Control and and Prevention Prevention National Center for Immunization and Respiratory Diseases Update on Vaccine Recommendations New Horizons in Pediatrics April
More informationExperience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada
Experience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada Jessica MacNeil, MPH Epidemiologist Centers for Disease Control and
More informationThis continuing education activity is co-sponsored by USF Health and by CME Outfitters, LLC.
This continuing education activity is co-sponsored by USF Health and by CME Outfitters, LLC. USF Health and CME Outfitters, LLC, gratefully acknowledge an educational grant from Pfizer Inc. in support
More information2018 CMS Web Interface
CMS Web Interface PREV-8: Pneumococcal Vaccination Status for Older AdultsMeasure Steward: NCQA CMS Web Interface V2.1 Page 1 of 18 06/25/ Contents INTRODUCTION...3 CMS WEB INTERFACE SAMPLING INFORMATION...4
More informationExpanded Use of PCV13 & PPV23
Expanded Use of PCV13 & PPV23 Dr. Jim Kellner Professor & Head Department of Pediatrics University of Calgary & Calgary Zone, Alberta Health Services Jim.Kellner@ahs.ca Objectives Explain the differences
More informationImmunizations. Update Immunizations through Time. Learning Objectives. Presenter Disclosure Information. 10:30 11:45am. Immunization Update
10:30 11:45am Immunization Update SPEAKER John Russell, MD Presenter Disclosure Information The following relationships exist related to this presentation: John Russell, MD, serves on Speaker s Bureau
More informationRxVaccinate. Support. Objectives. Disclosures 7/8/2013. Pneumococcal Immunization Update
RxVaccinate Pneumococcal Immunization Update Stephan L. Foster, Pharm.D., FAPhA, FNAP Professor and Vice-Chair College of Pharmacy University of Tennessee Health Science Center, Memphis, TN Liaison Member,
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE
Last Updated: Version 4.4 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Immunization Set Measure ID#: Measure Information Form Collected For: CMS Voluntary Only The Joint Commission
More informationPneumonia in Older Adults: An Update
Pneumonia in Older Adults: An Update - 2010 Suzanne F. Bradley, M.D. Professor of Internal Medicine Geriatrics & Infectious Diseases University of Michigan Medical School GRECC - VA Ann Arbor HCS ID Hospitalizations
More informationUpdate on Adult Immunization Strategies: Understanding the Current Recommendations
Update on Adult Immunization Strategies: Understanding the Current Recommendations EDWARD A. DOMINGUEZ, MD, FACP, FIDSA Medical Director, Organ Transplant Infectious Diseases Methodist Dallas Medical Center,
More informationImpact of vaccination on epidemiology in adults
Impact of vaccination on epidemiology in adults Jan Verhaegen 1. Data on prospective study on IPD in Belgium (2009-2011) 2. Evolution of capsular types of invasive isolates from adults after introduction
More informationSusan J. Rehm, MD, FACP, FIDSA Department of Infectious Disease Cleveland Clinic Cleveland, OH
Improving Adult Vaccination Practices Preventing Pneumococcal Disease in Your High-Risk and Older Patients Susan J. Rehm, MD, FACP, FIDSA Department of Infectious Disease Cleveland Clinic Cleveland, OH
More information2013 Adult Immunization Update. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle
2013 Adult Immunization Update David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Adult Immunization Update Pertussis Vaccine Influenza Vaccine Zoster
More information11/17/2013 THE WHO, WHAT, WHEN, AND WHY OF ADULT VACCINATIONS. Pneumococcal Vaccines for Adults (PPV) Pneumococcal Vaccines
THE WHO, WHAT, WHEN, AND WHY OF ADULT VACCINATIONS CAROL A. KAUFFMAN, MD VA ANN ARBOR HEALTHCARE SYSTEM UNIVERSITY OF MICHIGAN Will discuss: bacterial vaccines made of toxoids or polysaccharide capsular
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH Immunization Action Coalition Kentucky Immunization Conference Louisville, Kentucky October 14, 2015 Information in this presentation are valid as of
More informationImmunization Update Tamara Sheffield, MD, MPA, MPH
Immunization Update 2015 Tamara Sheffield, MD, MPA, MPH Disclosure I do not have any relevant financial relationships with any commercial interests I am a Medical Director employed by Intermountain Healthcare
More informationPneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections
Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths
More informationOREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS. PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine
OREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine Revisions as of 2/24/10 Pneumovax 23 should not be given concurrently with Zostavax
More informationImpacto de la vacuna conjugada en EUA
Impacto de la vacuna conjugada en EUA Richard Facklam, PhD, Distinguished Consultant, Retired, Centers for Disease Control and Prevention Atlanta, GA Bogotá, Colombia, February 2008 Pneumococcal Conjugate
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationVaccine Preventable Diseases Among Adults
Vaccine Preventable Diseases Among Adults Stephanie Borchardt, MPH, PhD Wisconsin Immunization Program Division of Public Health Wisconsin Department of Health Services November 17, 2016 At a Glance Burden
More informationImpact of pneumococcal conjugate vaccine: US experience Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA
Impact of pneumococcal conjugate vaccine: US experience Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA San Jose, Costa Rica, August 2007 Pneumococcal Conjugate Vaccine Introduction
More informationThese slides are the property of the presenter. Do not duplicate without express written consent.
Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable
More informationDeclarations. Objectives At the end of this presentation participants will be 7/25/2017. Dr. Mary Koslap Petraco has nothing to declare
Mary Koslap Petraco DNP, PNP BC, CPNP, FAANP Nurse Consultant Immunization Action Coalition Stony Brook University School of Nursing The Nurse Practitioner Association New York State 33 rd Annual Conference
More informationCharles Feldman. Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand
Opportunistic Infections Community Acquired Pneumonia Charles Feldman Professor of Pulmonology and Chief Physician Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand Introduction
More informationCHAMPS 2012 Immunization Update
CHAMPS 2012 Immunization Update with Iyabode A. Beysolow, M.D., M.P.H. National Center for Immunization and Respiratory Diseases Teleconference (HRSA Region VIII) July 25, 2012 7/19/2012 Disclosures Dr.
More information7/13/2016. Immunization Update Disclosures. Objectives. No financial disclosures to report
Immunization Update 2016 Courtney A. Robertson, PharmD Clinical Assistant Professor University of Louisiana at Monroe School of Pharmacy Disclosures No financial disclosures to report Objectives Pharmacists
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More informationLes 2 articles qui peuvent changer votre pratique sur: Vaccination et biothérapies
Les 2 articles qui peuvent changer votre pratique sur: Vaccination et biothérapies VZV Epidemiology and Pathogenesis 98% adults Respiratory spread 1,000,000/year and increasing CMI continuously boosted
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationChapter 16 Pneumococcal Infection. Pneumococcal Infection. August 2015
Chapter 16 16 PPV introduced for at risk 1996 PCV7 introduced for at risk 2002 and as routine 2008 PCV13 replaced PCV7 in 2010 NOTIFIABLE In some circumstances, advice in these guidelines may differ from
More informationAdult Pneumococcal Disease
Adult Pneumococcal Disease S. pneumoniae and pneumococcal disease The bacterium Streptococcus pneumoniae causes pneumococcal disease S. pneumoniae is commonly found in human nasopharynx (nose and throat)
More informationNew Vaccine Schedules. Disclosure. Overview. Immunization Recommendations in Primary Care. Objectives Pharmacists. Objectives Pharmacy Technicians
Disclosure Immunization Recommendations in Primary Care I have nothing to disclose. Betsy Blake, PharmD, BCPS October 2017 Objectives Pharmacists Learning Objectives: At the completion of this activity,
More informationBenefits of the pneumococcal immunisation programme in children in the United Kingdom
Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received
More informationWhy is surveillance important after introducing vaccines?
Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March
More informationACTIVITY DESCRIPTION
ACTIVITY DESCRIPTION FACULTY DISCLOSURES Burden of Vaccine-Preventable Diseases Each Year 226,000 hospitalizations due to influenza As many as 49,000 deaths 32,000 cases of invasive pneumococcal disease
More informationPrevention of pneumococcal disease in Canadian adults Old and New. Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto
Prevention of pneumococcal disease in Canadian adults Old and New Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto Objectives Review epidemiology of pneumococcal disease in adults
More informationPneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh
Pneumococcal vaccines Safety & Efficacy Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Disclosure Slide X X I DO NOT have any significant or other financial relationships with industry
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE August 30, 2010 EFFECTIVE DATE August 30, 2010 MEDICAL ASSISTANCE BULLETIN NUMBER 01-10-27, 08-10-28, 09-10-29, 31-10-30, 33-10-05 SUBJECT: Updates to the Medical Assistance Program Fee Schedule
More informationAdults need immunizations too!
Adults need immunizations too! Medicaid coverage, cost sharing, and provider reimbursement for ACIP-recommended immunizations for adults ABA Health Law Section Webinar January 16, 2018 Centers for Disease
More information2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
More informationKenneth McCall, BSPharm, PharmD Associate Professor UNE
Kenneth McCall, BSPharm, PharmD Associate Professor UNE Objectives Discuss the gap between current rates and Healthy People 2020 goals for vaccinations. Categorize each of the CDC recommended flu vaccines
More informationImmunization Update 2013 Across the Lifespan
Immunization Update 2013 Across the Lifespan Andrew Kroger M.D., M.P.H. Medical Officer, Centers for Disease Control and Prevention New York State Association of County Health Officials (NYSACHO) New York
More informationJon Temte, MD/PhD Chair Wisconsin Council on Immunization Practices Professor of Family Medicine and Community Health
Jon Temte, MD/PhD Chair Wisconsin Council on Immunization Practices Professor of Family Medicine and Community Health University of Wisconsin School of Medicine and Public Health Grand Rounds September
More informationS. Michael Marcy Memorial Lecture
S. Michael Marcy Memorial Lecture Lessons Learned from Making Vaccine Recommendations Larry K. Pickering, MD, FAAP April 16, 2016 Los Angeles, CA FINANCIAL DISCLOSURE: Larry K. Pickering, M.D., F.A.A.P.
More informationRethinking Recommendations for Use of Pneumococcal Vaccines in Adults
VACCINES Bruce Gellin and John F. Modlin, Section Editors INVITED ARTICLE Rethinking Recommendations for Use of Pneumococcal Vaccines in Adults Cynthia G. Whitney, 1 William Schaffner, 2 and Jay C. Butler
More informationMorbidity and Mortality Weekly Report
Morbidity and Mortality Weekly Report Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged 65 Years: Recommendations of the Advisory Committee
More informationUKnowledge. University of Kentucky
University of Kentucky UKnowledge Theses and Dissertations--Pharmacy College of Pharmacy 207 PNEUMOCOCCAL CONJUGATE VACCINE 3 COVERAGE IN CHILDREN, HIGH-RISK ADULTS 9-64 YEARS OF AGE, AND ADULTS OVER 65
More informationPrevention of Invasive Pneumococcal Disease (IPD)
Review Prevention of Invasive Pneumococcal Disease (IPD) Ioannis Tomos 1 MD, Elias Perros 2 MD, PhD, George Dimopoulos 3 MD, PhD, FCCP, FCCM 1 2 nd Pulmonary Department, ATTIKON University Hospital, Medical
More informationAdult Pneumococcal Disease
Adult Pneumococcal Disease S. pneumoniae and pneumococcal disease The bacterium Streptococcus pneumoniae causes pneumococcal disease S. pneumoniae is commonly found in human nasopharynx (nose and throat)
More information2018 Adult Immunization Schedule
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases 2018 Adult Immunization Schedule National Adult Immunization Coordinators Partnership Quarterly Meeting
More informationCurrent Status of PCV Use and WHO Recommendations
Current Status of PCV Use and WHO Recommendations SAGE 18 October 2017 Kate O Brien, MD MPH 1 Pneumonia remains a major cause of child deaths LMIC LMIC Pneumonia HIC HIC Pneumonia ~16% ~5% 2015 Black,
More informationUpdate on Adult Immunization Strategies: Understanding the Current Recommendations
Sunday CME Breakfast Update on Adult Immunization Strategies: Understanding the Current Recommendations Edward Dominguez, MD Medical Director, Organ Transplant Infectious Diseases Methodist Dallas Medical
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationDOES YOUR IMMUNIZATION KNOWLEDGE NEED A BOOSTER?: UPDATES FOR 2014
DOES YOUR IMMUNIZATION KNOWLEDGE NEED A BOOSTER?: UPDATES FOR 2014 Brandon Dionne, PharmD PGY2 Pharmacy Resident In Infectious Diseases University Of New Mexico College Of Pharmacy OBJECTIVES Explain general
More information10/4/2014 DOES YOUR IMMUNIZATION KNOWLEDGE NEED A BOOSTER?: UPDATES FOR 2014 OBJECTIVES CASE 1 IMMUNIZATION PRINCIPLES CASE 2
DOES YOUR IMMUNIZATION KNOWLEDGE NEED A BOOSTER?: UPDATES FOR 2014 Brandon Dionne, PharmD PGY2 Pharmacy Resident In Infectious Diseases University Of New Mexico College Of Pharmacy OBJECTIVES Explain general
More informationPneumococcal Vaccination. Bottom Line. Gangrene from Pneumococcal Bacteremia
Vaccination MSHO Performance Improvement Project Kristin L. Nichol, MD, MPH, MBA Professor of Medicine, University of Minnesota Chief of Medicine, Minneapolis VA Medical Cente Chair, MCAI Bottom Line disease
More informationCost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
Adv Ther (2014) 31:392 409 DOI 10.1007/s12325-014-0115-y ORIGINAL RESEARCH Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States Jieling Chen Megan A. O Brien H. Keri Yang John D.
More informationPneumococcal: Disease & Vaccine
Pneumococcal: Disease & Vaccine Wednesday 15 June 2016 Wednesday 28 June 2016 Start time in your state: 7:30pm = QLD, NSW, VIC, TAS, ACT 7:00pm = SA, NT 5:30pm = WA Your presenter tonight Angela Newbound,
More informationPneumococcal vaccination for older persons. No. 2018/05. Executive summary
Pneumococcal vaccination for older persons No. 2018/05 Executive summary Executive summary Pneumococcal vaccination for older persons page 2 of 6 Many people carry pneumococcal bacteria without becoming
More informationUNIVERSITY OF CALGARY. (IPD) in Adults with Underlying Comorbidities. Jason Lee Cabaj A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES
UNIVERSITY OF CALGARY The Influence of Childhood Conjugate Vaccine Introduction on Invasive Pneumococcal Disease (IPD) in Adults with Underlying Comorbidities by Jason Lee Cabaj A THESIS SUBMITTED TO THE
More informationDisclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives
Pharmacist Learning Objectives No Spleen? No Problem. A Review of Vaccinations Indicated for the Asplenic Patient SCSHP Fall Meeting October 26, 2017 Explain the rationale for vaccinations in Select the
More informationAndrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010
2010 Immunization Update Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 Disclosures No financial conflict
More informationcontinuing education for pharmacists
continuing education for pharmacists Pneumococcal Disease: Treatment and Prevention Volume XXXIV, No. 3 Donald L. Bennett, R.Ph., MBA, Clinical Assistant Professor, The Ohio State University College of
More informationAdult Immunization Rates
Adult Immunization Rates California Immunization Coalition Summit May 5, 2014 Eileen Yamada, MD, MPH California Department of Public Health Immunization Branch Adult Immunization Rates California Data
More informationUpdate on Immunizations H. Keipp Talbot, M.D., M.P.H.
Update on Immunizations H. Keipp Talbot, M.D., M.P.H. Vanderbilt University Medical Center 1 DISCLOSURES Financial Relationships with Relevant Commercial Interests Receive research funding from Sanofi
More informationTitle: Enhancing state-based surveillance for invasive pneumococcal disease
09-ID-06 Committee: Infectious Diseases Title: Enhancing state-based surveillance for invasive pneumococcal disease I. tatement of the Problem: Cases of invasive pneumococcal disease among children less
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationSeptember 14, All Medical Providers and Health Care Facilities. NYSDOH Bureau of Immunization
September 14, 2009 TO: FROM: All Medical Providers and Health Care Facilities NYSDOH Bureau of Immunization HEALTH ADVISORY: Novel H1N1 Influenza Vaccine Information Please distribute to the Infection
More informationImmunizations to Reduce Disease H. Keipp Talbot, M.D., M.P.H.
Immunizations to Reduce Disease H. Keipp Talbot, M.D., M.P.H. Vanderbilt University School of Medicine 1 DISCLOSURES Financial Relationships with Relevant Commercial Interests Receive research funding
More informationGlobal Evolution of the Pneumococcus and the Impact of Vaccination Keith P. Klugman
Global Evolution of the Pneumococcus and the Impact of Vaccination Keith P. Klugman Department of Global Health, Rollins School of Public Health and Division of Infectious Diseases, School of Medicine
More informationGeorgia State University. Georgia State University. Jorge E. Arana. Spring
Georgia State University ScholarWorks @ Georgia State University Public Health Theses School of Public Health Spring 5-7-2011 Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal
More informationHPV VACCINATION ROUTINELY RECOMMENDING CANCER PREVENTION
National Center for Immunization & Respiratory Diseases HPV VACCINATION ROUTINELY RECOMMENDING CANCER PREVENTION Melinda Wharton, MD, MPH Director, Immunization Services Division Mississippi Primary Health
More informationRisk and Prevention of Pneumococcal Disease in Adults
Risk and Prevention of Pneumococcal Disease in Adults Athena 2015. International Conference Antoni Torres. University of Barcelona 1 Pneumococcal pneumonia represents the majority of pneumococcal disease*
More information